This protocol addresses patients with a confirmed diagnosis of gestational choriocarcinoma who are classified as low risk by the WHO modified prognostic index score for gestational trophoblastic neoplasm (GTN)—specifically, those with a total score of 0 to 6.

Clinical Scenario

Gestational choriocarcinoma with a WHO modified prognostic index score of 0 to 6. This score defines the low-risk group (score below 7), which determines the appropriate chemotherapy intensity: single-agent chemotherapy for low risk, versus multi-agent regimens reserved for high risk (score 7 or higher).

Treatment Approach (First-Line)

Low-risk patients in this group are treated with a single-agent chemotherapy approach—methotrexate-based regimens are among the first-line options endorsed by major international guidelines. The complete regimen, schedule, and consolidation strategy are detailed in the full protocol.

Clinical Goal

The primary treatment endpoint is normalization of serum human chorionic gonadotropin (hCG), monitored at regular intervals throughout therapy until values normalize.

References

This group includes patients with a diagnosis of gestational choriocarcinoma who receive a score from 0 to 6 according to the WHO modified prognostic index score for GTN.
Consider using single-agent chemotherapy in low-risk (score <7) and multi-agent chemotherapy in high risk (score of 7 or more).
This group of patients should be treated with single-agent methotrexate (plus leucovorin) or actinomycin D chemotherapy.
During chemotherapy serum hCG levels should be monitored every 1 to 2 weeks until hCG values normalize, then additional cycles of consolidation should be administered.

DOI: 10.1136/ijgc-2023-004704 View source ↗

First-Line Treatment of Low-Risk Gestational Choriocarcinoma with WHO Modified Prognostic Index Score 0–6

References